vedolizumab

Pertuzumab, trastuzumab, and hyaluronidase is a subcutaneous fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase. Replacing hours of IV infusion with 15-minute subcutaneous administration, it revolutionizes outpatient convenience and marks a milestone in breast cancer treatment delivery.

Ranibizumab is an anti-VEGF-A Fab fragment for wet AMD and DME. As the gold standard in ophthalmic anti-VEGF therapy, it established the foundation of the retinal disease drug market, with clear biosimilar substitution potential post-patent expiry.

Risankizumab is an anti-IL-23 p19 mAb for psoriasis, Crohn's disease, and ulcerative colitis. With industry-leading PASI 90 response rates and q12w maintenance dosing, it offers exceptional compliance and ranks among the fastest-growing assets in immunology.

Romiplostim is a TPO receptor agonist peptibody for immune thrombocytopenia (ITP). As the standard second-line therapy with long-acting subcutaneous design, it remains effective in splenectomy-refractory patients, leading the hematology niche market.

Secukinumab is an anti-IL-17A mAb and the pathway leader in psoriasis, ankylosing spondylitis, and psoriatic arthritis. With industry-leading long-term PASI 100 clearance rates, it is a mature, high-volume immunology asset with stable market share.

Trastuzumab deruxtecan is a HER2-directed ADC that pioneered therapy for HER2-low breast cancer. The DESTINY program has reshaped global guidelines, with massive cross-tumor potential across breast, gastric, and lung cancers, setting the ADC technology benchmark.

Abaloparatide is a PTHrP(1-34) analog acting as an agonist at the PTH1 receptor (PTH1R). It activates the cAMP signaling pathway to stimulate osteoblastic activity and new bone formation. Administered as 80 mcg subcutaneously once daily. Abaloparatide demonstrates rapid and robust bone formation with the b...

Amphotericin B is a true single bilayer liposomal drug delivery system with amphotericin B intercalated within a liposomal membrane composed of hydrogenated soy phosphatidylcholine, distearoyl phosphatidylglycerol, and cholesterol. Liposomes are less than 100 nm in diameter. The liposomal encapsulation per...

Aprepitant, a highly selective neurokinin-1 receptor antagonist, provides superior protection against both acute and delayed chemotherapy-induced nausea and vomiting compared to conventional antiemetic agents, with a single dose offering sustained efficacy over many hours. Its ability to be combined with 5...

Atezolizumab is an anti-PD-L1 mAb and the first approved for NSCLC first-line immunotherapy combinations. With differentiated positioning in urothelial carcinoma and HCC (combined with bevacizumab), it remains a significant competitor in the PD-L1 landscape.

Bevacizumab is a humanized anti-VEGF-A mAb inhibiting tumor angiogenesis across multiple solid tumors. As the cornerstone anti-angiogenic agent with broad combination potential, it commands massive market volume with an established biosimilar competitive landscape.

Bupivacaine utilizes proprietary DepoFoam technology to encapsulate bupivacaine within multivesicular liposomes, enabling sustained analgesia for up to 72 hours through a unique tri-phasic release mechanism involving initial burst, membrane diffusion, and particle erosion. This prolonged duration of action...